Roche buys full rights to danoprevir from InterMune
This article was originally published in Scrip
Executive Summary
Roche has bought full global development and commercialisation rights to danoprevir (RG7227/ITMN-191) from InterMune for $175 million, leaving InterMune with the troublesome pirfenidone as its principal in-house asset.